Lutetium treatment is a peptide receptor isotope treatment where lutetium isotope (Lu-177) is the radiating substance. The treatment is suitable mainly with tumours that are found to contain somatostatin receptors. The method is typically used to treat metastasized neuroendocrine tumours (e.g. GEP-NET) in the intestines, for example (“carcinoid tumours”). These tumours are relatively rare.
During the treatment, the radiopharmaceutical is given as an infusion and, at the same time, the patient is given a nephroprotective dose of amino acid solution and/or plasma expander.
After the infusion, the radiation dose in the tumour and in the organs is determined with the help of SPECT-CT imaging. After the radiopharmaceutical infusion, the isotope distribution is tracked with multiple imaging sessions, sometimes up to one week after the treatment.
The technique is so demanding that peptide receptor treatments have been centralised to a few centres worldwide. Until now, Finnish patients have been treated abroad, mainly in Uppsala. Docrates Cancer Center started regular lutetium treatments in the spring of 2010.
Lutetium has a powerful destructive effect on the tumour cells, but its range is short, only 2 millimetres. For this reason, the treatment series consist of four sessions every 8–10 weeks. In some cases the treatment may be curative, but it is also used to control cancer symptoms.
Lutetium treatment can be combined with drug and radiation therapies. The isotope yttrium-90 can be used in peptide receptor treatment, which has a longer range than lutetium, up to 11 mm, and a shorter half-life. Yttrium-90 is not as radioactive as lutetium-177, but its range is broader. Yttrium-90 also radiates less into the environment than Lu-177. Neither treatment poses a danger to the environment due to the radiation levels. The day following the treatment is spent in the hospital.
Yttrium treatments are given in series of two treatments every 8–12 weeks. The isotope treatments are planned on the basis of the diagnosis and the dose calculation measurements or, in other words, based on SPECT-CT imaging.
A multi-professional team, led by nuclear medicine docent and specialist Kalervi Kairemo, is in charge of peptide receptor treatment at Docrates Cancer Center.